卫宁健康(300253.SZ)拟回购注销10.142万股限制性股票
格隆汇12月17日丨卫宁健康(300253.SZ)公布,鉴于6名首次授予限制性股票、7名预留授予限制性股票激励对象因个人原因离职,不再具有激励对象资格及1名预留授予限制性股票激励对象上一年度个人绩效考核结果为“不合格”,未达到当期解锁条件,根据公司《2016年股权激励计划(草案)》的相关规定,拟对上述不符合解锁条件的限制性股票回购注销。
首次授予限制性股票5.187万股,预留授予限制性股票4.955万股,共计10.142万股。
首次授予限制性股票回购价格为5.842元/股,预留授予限制性股票回购价格为3.625元/股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.